On February 24, 2014, VIVUS, Inc., (NASDAQ:VVUS) issued a press release regarding its financial results for the fourth quarter and year ended December 31, 2013, a business update and certain other information. The full text of the press release concerning the foregoing is furnished herewith as Exhibit 99.1. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $6.99 in last session, and closed at $6.75, while the day range of VIVUS, Inc. (NASDAQ:VVUS) stock is $6.59 – $6.99. The stock showed a positive weekly performance of -1.03%.
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) has worked hard in the last three years to see a few of its drugs being approved by the Food and Drug Administration before selling them to the public. However, the company already has a few feathers under its cap. One of them is that its obesity-fighting drug, Belviq, was the first to enjoy FDA’s approval in the last thirteen years, prior to 2012. When it signed a new deal with Eisai to help with marketing this new obesity drug, it immediately received $60 million from the latter upfront. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened at $6.95 in last session, and closed at $7.01 by gaining 1.30%. The 52 week range of $4.05 – $9.25. Company’s market capitalization is $1.53B.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 21 said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board. The company said Alex Denner – investor Carl Icahn’s former healthcare lieutenant and Sarissa’s chief investment officer – will assume one of the seats. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock decreased -2.71% and finished the last session at $8.63. The EPS of the stock remained -1.46. Company’s market capitalization is $1.60B.
Shares of MannKind Corp. (NASDAQ:MNKD) saw unusually large options trading activity on Monday. Stock traders acquired 12,443 call options on the stock, Stock Ratings Network reports. This is an increase of approximately 120% compared to the average daily volume of 5,661 call options. MannKind Corporation (NASDAQ:MNKD) stock opened the session at $6.08, and closed the session at $6.40. The 52 week range of the MannKind Corporation (NASDAQ:MNKD) stock remained $2.48 – $8.70 and the day range was $6.06 – $6.50.
Leave a Reply